Entries by Georg Kääb

SRTD raises €31.5M seed round to develop cell-selective RNA therapies

Germany-based biotech company SRTD Biotech has closed a €31.5 million seed funding round. At the heart of its approach is an RNA technology designed to address a fundamental challenge facing many RNA-based therapies: How can the activity of a therapeutic molecule be restricted to specific cells without unnecessarily harming healthy tissue?

Swiss VC Redalpine closes eighth fund at $250 million

Swiss venture capital investor Redalpine has closed its eighth fund at $250 million. Redalpine Capital VIII reached its hard cap and was oversubscribed, according to the firm. Less than 12 months passed between the first and final closings. In what remains a challenging fundraising environment for European venture capital firms, this represents a relatively quick closing.

Spinal muscular atrophy: Tumors reported following Novartis gene therapy

Nine reports of tumors in children treated with Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma raise new questions about its long-term safety. In two cases, viral vector DNA was detected in the patients’ genomes. In 2022, two children had already died of acute liver failure following treatment. The cases illustrate why assessing the safety of gene and cell therapies remains a particular challenge.

Boehringer secures six Chinese cancer programs in deal worth up to $7B

Boehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical programs involving antibody-drug conjugates (ADCs) and T-cell engagers are expected to strengthen its oncology pipeline. Boehringer will initially pay $358 million, with up to another $7 billion tied to development and commercial milestones.

BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver

The Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report also shows how much work remains: Pumitamig is at the center of clinical development, while other advanced candidates still need to confirm their results. In the meantime, BioNTech is also facing setbacks in its mRNA cancer programs. The collaboration with Bristol Myers Squibb has become a major pillar of revenue — although primarily through contractual payments rather than drug sales.

Bayer closes the gap with Boehringer in China’s lung cancer race

Bayer brings sevabertinib into the first-line setting in China — but Boehringer is already there: With the approval of sevabertinib for the first-line treatment of HER2-mutated lung cancer, Bayer is expanding access to an important market. The drug is no longer entirely new, nor is it the first in its class in China. Boehringer Ingelheim has already secured a head start with zongertinib.

Fresenius turns to WuXi to add up to 37 biosimilars to its pipeline

Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics approach the end of their patent protection and biosimilars could become an important tool for health care systems to contain costs. Fresenius aims to double its biosimilar revenue to nearly €2 billion, bringing Sandoz’s league at least within sight.

TME Pharma returns to its roots, looks to Japan to rescue NOX-A12

From Berlin biotech NOXXON through a strategic realignment and considerations of cryptocurrency investments, and now back to drug development: TME Pharma has found a potential partner for its lead drug candidate NOX-A12 in Japanese biotech company TMS. For now, however, the companies are only entering exclusive negotiations. Whether these will actually lead to funded clinical development remains uncertain.

Molecular Partners halves its workforce — is money running short?

Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 jobs. According to the company, its cash reserves will last until the end of 2027. But behind the strategic overhaul lies an increasingly strained financial position. Its broad pipeline is likely to require much stricter prioritization.

Immatics shows off its PRAME bispecific data at ESMO 2026

Germany-based cancer immunotherapy specialist Immatics presented updated clinical data for two PRAME-targeted drug candidates at the ESMO Congress 2026 in Madrid. Particularly striking is the survival signal for the bispecific T-cell engager IMA402: In a subgroup of patients with advanced melanoma and high PRAME expression, 91% were still alive after one year. Median overall survival had not yet been reached at the time of analysis.